Fennec Pharmaceuticals Q2 2025: Unpacking Key Contradictions in Patient Adherence, Production Timelines, and Market Strategies

Patient adherence to PEDMARK, Yokogawa's production and supply chain, PEDM-11 clinical trial progress, EU market launch expectations, AYA and pediatric market focus are the key contradictions discussed in Fennec Pharmaceuticals' latest 2025Q2 earnings call.



Revenue Growth and Market Penetration:
- Fennec Pharmaceuticals achieved net revenues of $9.7 million for Q2 2025, marking a 33% year-over-year increase and 10% sequential growth.
- This revenue growth was driven by disciplined execution, a revamped go-to-market strategy, and a top-down focus on talent, leading to the addition of 14 new accounts and enhanced demand for PEDMARK.

Strategic Imperatives and Product Adoption:
- Fennec has seen three consecutive quarters of growth, with a focus on stabilizing the business and building sustainable growth.
- This growth is attributed to a focused set of strategic imperatives, including increasing awareness of PEDMARK's benefits, expanding patient support services, and enhancing clinical adoption, particularly in AYA settings.

Payer and Provider Access Expansion:
- The company has achieved significant progress with payers and providers, leading to improved coverage and reduced barriers for sites ready to treat with PEDMARK.
- This is due to the strengthening of the Fennec HEARS patient assistance program and improved healthcare provider practices, patient services, and reimbursement support.

International Partnership and EU Market Expansion:
- The partnership with Norgine for the EU market has started to show traction, with positive indications from the U.K. and Germany, and plans to expand to additional EU5 countries by early 2026.
- This expansion is expected to contribute to future growth as PEDMARK gains traction in these markets, supported by the Norgine partnership's royalty and milestone components.